1. Medtech Insight
  2. >>Leadership

Exec Chat: Steven Mickelsen Helps Acutus Translate Science Into Improved Outcomes

 
• By Reed Miller

Mickelsen, an electrophysiologist at the University of Iowa, recently joined the rapidly growing San Diego-area company as Chief Translational Science Officer and is helping to guide the company’s development of novel electrophysiology therapies to treat cardiac arrhythmias.

AcQMap non-contact charge density cardiac mapping system
AcQMap non-contact charge density cardiac mapping image • Source: Acutus Medical

Steven Mickelsen joined Acutus Medical, Inc. as its first chief translational science officer to help the company bridge the gap between science and medicine in the development of the next generation of cardiac arrhythmia management technologies.

Mickelsen is a practicing cardiac electrophysiologist at the University of Iowa Hospitals and Clinics in Iowa City, where he is also a professor of cardiovascular medicine and internal medicine. He was a Howard Hughes Research Scholar at the National Institutes of Health and completed his internal medicine residency and clinical research at the Mayo Clinic. In 2012, Mickelsen founded Farapulse Inc

More from Leadership

More from Medtech Insight

Faster Device Certification Among Keys To Unlocking Innovation In EU MedTech Sector

 
• By Amanda Maxwell

While MedTech Europe sharpens its focus on what the EU most urgently needs to advance the medtech market in four targeted measures, the European Commission has also unveiled four priorities for 2025.

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By Shubham Singh

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By Marion Webb

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.